WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
PEGS Boston
-
ASGCT Annual Meeting 2026
-
BioBeat 2026
-
SLAS Europe 2026
Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models
Ambient-temperature preservation solution enables reliable storage and shipment of organoids and spheroids, to support growing adoption of New Approach Methodologies Newcastle, UK, 21 April 2026: Atelerix, a biotech company revolutionising [...]
Atelerix forms strategic partnership with JH Health Ltd to expand non-cryogenic cell preservation capabilities in the Middle East
Agreement grants JH Health exclusive rights to use and distribute Atelerix’s portfolio of non-cryogenic preservation solutions in the region Expands regional capabilities with funding for high-volume local manufacturing, as well [...]
Bio-Rad Extends Range of Anti-Idiotypic Antibodies and Anti-Fc Mutation Antibodies for Bioanalysis and Drug Monitoring
Expanded antibody portfolio enhances detection of biologics and YTE-modified therapeutics for bioanalytical applications HERCULES, Calif.—April 14, 2026—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research [...]




















